RMEI Medical Education’s Post

Learn about the importance of biomarker testing in #cervical cancer and frontline treatment options for PD-L1+ persistent, recurrent, or metastatic disease in this CME activity. #RMEI #CME #MedEd https://ow.ly/weIc50Qusag

Learn about the importance of biomarker testing in #cervical cancer and frontline treatment options for PD-L1+ persistent, recurrent, or metastatic disease in this CME activity. #RMEI #CME #MedEd https://ow.ly/weIc50Qusag

Expiring soon! Learn about the importance of biomarker testing in #cervical cancer and frontline treatment options for PD-L1+ persistent, recurrent, or metastatic disease in this CME activity. #RMEI #CME #MedEd https://ow.ly/weIc50Qusag

Introducing a new "OvaView" summary featuring Victoria Haverbusch, our expert in risk assessment. Explore the latest advancements in biomarker technology for assessing ovarian cancer risk in a concise video and gain valuable insights to enrich your clinical decision-making process. #OvaView #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth

Introducing a new “OvaView” summary featuring Victoria Haverbusch, our expert in risk assessment. Explore the latest advancements in biomarker technology for assessing ovarian cancer risk in a concise video and gain valuable insights to enrich your clinical decision-making process.   #OvaView #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth

I challenge you to listen to the latest edition of OvaView with Victoria Haverbusch and not get excited about #OvaWatch.This one-of-a-kind proprietary blood test has demonstrated its accuracy in assessing the risk of malignancy in women with an adnexal mass, a breakthrough by any measure. For far too long, a lack of confidence in non-invasive methods of assessing ovarian cancer risk has led us to resort to surgical intervention even though the vast majority of the masses turn out to be benign. Aspira Women's Health is going to change that. The use of #OvaWatch initial clinical assessment and ongoing mass monitoring can reduce unnecessary surgery and surgical menopause while simultaneously improving a clinician's ability to identify those patients that require additional care and clinical intervention. #obgyn #innovation #dx #ovariancancer #gynecology #womenshealth #nursepractitioner

🧐Check out the #Review “Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer”  📜Read more here: https://lnkd.in/dQ4YbwDh  #sargramostim #GMCSF #irAE

In advanced cancer care, the complexity of polypharmacy often leads to serious side effects, adverse drug events, and medication inefficacy. A recent study shows that targeted palliative care, focusing on the most impactful symptoms, can reduce the need for extensive medications and improve patient quality of life. With advanced technology enabling earlier cancer detection, we can further minimize the challenges of polypharmacy and enhance patient outcomes. https://bit.ly/3SCRYy3 #CancerCare #Polypharmacy #HealthcareInnovation #PalliativeCare

A delayed diagnosis could impact on your life - learn five symptoms of Ovarian Cancer to be cautious of. #OvarianCancerAwarenessMonth #KnowTheSigns

Have you read the Deep Dives in the Quarterly Drug Pipeline yet? In this edition, we explore therapies for rare diseases — like neiman-pick disease type 2 and classic galactosemia — and feature new treatments for chronic graft versus host disease (cGVHD), gastroparesis, hereditary angioedema (HAE), and biliary tract cancer. Don't miss this quarter's pipeline here: https://bit.ly/3SlkTXi